Serina Therapeutics files investor presentation with preliminary 2024 data; no specific figures disclosed

Serina Therapeutics, Inc.

Exhibit 99.1 provides a presentation highlighting Serina's POZ Platform for drug delivery.
Filing states preliminary unaudited financial info as of Dec 31, 2024, but these figures are not included in the filing text or exhibit excerpt.
Presentation mentions RNA delivery and improved ADCs, but no revenue, cash, or other concrete financial metrics are given.
The company is an emerging growth company; audit of full-year 2024 results is ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.